{"entity":{"type":"insider","cik":"0001856078","url":"/insider/0001856078","json_url":"/insider/0001856078.json","name":"DeLong Mark Jeffrey","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":28,"n_filings":27,"first":"2021-05-19","last":"2026-02-13","span_basis":"filed_date"},"name_variants":[{"name":"DeLong Mark Jeffrey","source":"filing","n_filings":27,"first_seen":"2021-05-19","last_seen":"2026-02-13"}],"transactions":[{"id":5765644,"accession":"0001492422-26-000083","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001492422-26-000083","line_url":"/filing/0001492422-26-000083#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":368.0,"shares_display":"368","price_per_share":22.1537,"price_display":"22.15","price_state":"stated","total_value":8152.5616,"total_display":"8,152.56","total_whole":"8,153","shares_owned_after":114591.0,"shares_owned_after_display":"114,591","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-11","filed_date":"2026-02-13","scope":"insider"},{"id":5960950,"accession":"0001492422-26-000059","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001492422-26-000059","line_url":"/filing/0001492422-26-000059#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3371.0,"shares_display":"3,371","price_per_share":21.7654,"price_display":"21.77","price_state":"stated","total_value":73371.1634,"total_display":"73,371.16","total_whole":"73,371","shares_owned_after":78353.0,"shares_owned_after_display":"78,353","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-22","filed_date":"2026-01-23","scope":"insider"},{"id":5960945,"accession":"0001492422-26-000043","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001492422-26-000043","line_url":"/filing/0001492422-26-000043#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1334.0,"shares_display":"1,334","price_per_share":19.7929,"price_display":"19.79","price_state":"stated","total_value":26403.7286,"total_display":"26,403.73","total_whole":"26,404","shares_owned_after":81724.0,"shares_owned_after_display":"81,724","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-20","filed_date":"2026-01-21","scope":"insider"},{"id":5881413,"accession":"0001492422-26-000030","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001492422-26-000030","line_url":"/filing/0001492422-26-000030#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1780.0,"shares_display":"1,780","price_per_share":22.1872,"price_display":"22.19","price_state":"stated","total_value":39493.216,"total_display":"39,493.22","total_whole":"39,493","shares_owned_after":83058.0,"shares_owned_after_display":"83,058","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-13","filed_date":"2026-01-15","scope":"insider"},{"id":4957103,"accession":"0001127602-25-004328","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-25-004328","line_url":"/filing/0001127602-25-004328#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":363.0,"shares_display":"363","price_per_share":28.5388,"price_display":"28.54","price_state":"stated","total_value":10359.5844,"total_display":"10,359.58","total_whole":"10,360","shares_owned_after":83945.0,"shares_owned_after_display":"83,945","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-11","filed_date":"2025-02-12","scope":"insider"},{"id":4328355,"accession":"0001127602-25-002373","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-25-002373","line_url":"/filing/0001127602-25-002373#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":365.0,"shares_display":"365","price_per_share":29.5236,"price_display":"29.52","price_state":"stated","total_value":10776.114,"total_display":"10,776.11","total_whole":"10,776","shares_owned_after":84308.0,"shares_owned_after_display":"84,308","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-29","filed_date":"2025-01-30","scope":"insider"},{"id":4348986,"accession":"0001127602-25-001831","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-25-001831","line_url":"/filing/0001127602-25-001831#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1396.0,"shares_display":"1,396","price_per_share":30.4255,"price_display":"30.43","price_state":"stated","total_value":42473.998,"total_display":"42,474.00","total_whole":"42,474","shares_owned_after":84673.0,"shares_owned_after_display":"84,673","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-22","filed_date":"2025-01-23","scope":"insider"},{"id":4030433,"accession":"0001127602-25-001616","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-25-001616","line_url":"/filing/0001127602-25-001616#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1235.0,"shares_display":"1,235","price_per_share":29.9582,"price_display":"29.96","price_state":"stated","total_value":36998.377,"total_display":"36,998.38","total_whole":"36,998","shares_owned_after":57561.0,"shares_owned_after_display":"57,561","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-17","filed_date":"2025-01-21","scope":"insider"},{"id":4328278,"accession":"0001127602-25-001185","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-25-001185","line_url":"/filing/0001127602-25-001185#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1599.0,"shares_display":"1,599","price_per_share":28.7021,"price_display":"28.70","price_state":"stated","total_value":45894.6579,"total_display":"45,894.66","total_whole":"45,895","shares_owned_after":58796.0,"shares_owned_after_display":"58,796","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-13","filed_date":"2025-01-14","scope":"insider"},{"id":3067846,"accession":"0001127602-24-010605","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-010605","line_url":"/filing/0001127602-24-010605#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9913.0,"shares_display":"9,913","price_per_share":56.9,"price_display":"56.90","price_state":"stated","total_value":564049.7,"total_display":"564,049.70","total_whole":"564,050","shares_owned_after":54693.0,"shares_owned_after_display":"54,693","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-18","filed_date":"2024-03-19","scope":"insider"},{"id":2624444,"accession":"0001127602-24-004711","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-004711","line_url":"/filing/0001127602-24-004711#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":597.0,"shares_display":"597","price_per_share":67.7669,"price_display":"67.77","price_state":"stated","total_value":40456.8393,"total_display":"40,456.84","total_whole":"40,457","shares_owned_after":64606.0,"shares_owned_after_display":"64,606","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-12","filed_date":"2024-02-13","scope":"insider"},{"id":3155038,"accession":"0001127602-24-002734","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-002734","line_url":"/filing/0001127602-24-002734#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":367.0,"shares_display":"367","price_per_share":64.1382,"price_display":"64.14","price_state":"stated","total_value":23538.7194,"total_display":"23,538.72","total_whole":"23,539","shares_owned_after":65203.0,"shares_owned_after_display":"65,203","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-29","filed_date":"2024-01-31","scope":"insider"},{"id":2838373,"accession":"0001127602-24-001931","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-001931","line_url":"/filing/0001127602-24-001931#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1384.0,"shares_display":"1,384","price_per_share":64.996,"price_display":"65.00","price_state":"stated","total_value":89954.464,"total_display":"89,954.46","total_whole":"89,954","shares_owned_after":65570.0,"shares_owned_after_display":"65,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-22","filed_date":"2024-01-23","scope":"insider"},{"id":2373364,"accession":"0001127602-24-001438","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-24-001438","line_url":"/filing/0001127602-24-001438#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1631.0,"shares_display":"1,631","price_per_share":66.8086,"price_display":"66.81","price_state":"stated","total_value":108964.8266,"total_display":"108,964.83","total_whole":"108,965","shares_owned_after":66954.0,"shares_owned_after_display":"66,954","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-16","filed_date":"2024-01-17","scope":"insider"},{"id":8625486,"accession":"0001127602-23-026187","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-026187","line_url":"/filing/0001127602-23-026187#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Chief Business & Strat Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business & Strat Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business & Strat Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":131.0,"shares_display":"131","price_per_share":46.0362,"price_display":"46.04","price_state":"stated","total_value":6030.7422,"total_display":"6,030.74","total_whole":"6,031","shares_owned_after":51622.0,"shares_owned_after_display":"51,622","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-23","filed_date":"2023-10-24","scope":"insider"},{"id":6521934,"accession":"0001127602-22-021302","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-021302","line_url":"/filing/0001127602-22-021302#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":69.5,"price_display":"69.50","price_state":"stated","total_value":347500.0,"total_display":"347,500.00","total_whole":"347,500","shares_owned_after":29250.0,"shares_owned_after_display":"29,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-17","filed_date":"2022-08-18","scope":"insider"},{"id":6747543,"accession":"0001127602-22-020885","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-020885","line_url":"/filing/0001127602-22-020885#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":67.0,"price_display":"67.00","price_state":"stated","total_value":335000.0,"total_display":"335,000.00","total_whole":"335,000","shares_owned_after":29250.0,"shares_owned_after_display":"29,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-11","filed_date":"2022-08-12","scope":"insider"},{"id":6817127,"accession":"0001127602-22-020734","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-020734","line_url":"/filing/0001127602-22-020734#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":64.5,"price_display":"64.50","price_state":"stated","total_value":322500.0,"total_display":"322,500.00","total_whole":"322,500","shares_owned_after":29250.0,"shares_owned_after_display":"29,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-08","filed_date":"2022-08-09","scope":"insider"},{"id":6111865,"accession":"0001127602-22-020673","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001127602-22-020673","line_url":"/filing/0001127602-22-020673","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":60.75,"price_display":"60.75","price_state":"stated","total_value":607500.0,"total_display":"607,500.00","total_whole":"607,500","shares_owned_after":29250.0,"shares_owned_after_display":"29,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-04","filed_date":"2022-08-08","scope":"insider","n_lines":2},{"id":6308954,"accession":"0001127602-22-019858","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-019858","line_url":"/filing/0001127602-22-019858#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":57.0,"price_display":"57.00","price_state":"stated","total_value":285000.0,"total_display":"285,000.00","total_whole":"285,000","shares_owned_after":29250.0,"shares_owned_after_display":"29,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-27","filed_date":"2022-07-28","scope":"insider"},{"id":6858492,"accession":"0001127602-22-019579","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-019579","line_url":"/filing/0001127602-22-019579#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":56.42,"price_display":"56.42","price_state":"stated","total_value":282100.0,"total_display":"282,100.00","total_whole":"282,100","shares_owned_after":29250.0,"shares_owned_after_display":"29,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-19","filed_date":"2022-07-21","scope":"insider"},{"id":6405497,"accession":"0001127602-22-017896","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-017896","line_url":"/filing/0001127602-22-017896#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":41.785,"price_display":"41.78","price_state":"stated","total_value":417850.0,"total_display":"417,850.00","total_whole":"417,850","shares_owned_after":29250.0,"shares_owned_after_display":"29,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-16","filed_date":"2022-06-21","scope":"insider"},{"id":6521364,"accession":"0001127602-22-012442","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-012442","line_url":"/filing/0001127602-22-012442#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7000.0,"shares_display":"7,000","price_per_share":52.53,"price_display":"52.53","price_state":"stated","total_value":367710.0,"total_display":"367,710.00","total_whole":"367,710","shares_owned_after":28481.0,"shares_owned_after_display":"28,481","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-20","filed_date":"2022-04-22","scope":"insider"},{"id":5004520,"accession":"0001127602-21-022382","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-21-022382","line_url":"/filing/0001127602-21-022382#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":65.0,"price_display":"65.00","price_state":"stated","total_value":65000.0,"total_display":"65,000.00","total_whole":"65,000","shares_owned_after":9490.0,"shares_owned_after_display":"9,490","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-21","filed_date":"2021-07-22","scope":"insider"},{"id":4215600,"accession":"0001127602-21-022141","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-21-022141","line_url":"/filing/0001127602-21-022141#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":62.3,"price_display":"62.30","price_state":"stated","total_value":62300.0,"total_display":"62,300.00","total_whole":"62,300","shares_owned_after":9490.0,"shares_owned_after_display":"9,490","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-15","filed_date":"2021-07-16","scope":"insider"},{"id":4170961,"accession":"0001127602-21-020052","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-21-020052","line_url":"/filing/0001127602-21-020052#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":64.9575,"price_display":"64.96","price_state":"stated","total_value":259830.0,"total_display":"259,830.00","total_whole":"259,830","shares_owned_after":9490.0,"shares_owned_after_display":"9,490","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-16","scope":"insider"},{"id":5060416,"accession":"0001127602-21-017369","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-21-017369","line_url":"/filing/0001127602-21-017369#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001856078","owner_name":"DeLong Mark Jeffrey","owner_display_name":"DeLong Mark Jeffrey","owner_url":"/insider/0001856078","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":55.0,"price_display":"55.00","price_state":"stated","total_value":110000.0,"total_display":"110,000.00","total_whole":"110,000","shares_owned_after":9490.0,"shares_owned_after_display":"9,490","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-18","filed_date":"2021-05-19","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":28,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":28,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":28},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001492422","name":"Apellis Pharmaceuticals, Inc.","url":"/issuer/0001492422","role":"Officer (Chief Business & Strat Officer)","n_filings":27,"first_seen":"2021-05-19","last_seen":"2026-02-13"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001856078","retrieved_at":"2026-08-25T01:06:26+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}